The 8-aminoquinoline tafenoquine (TFQ), a primaquine derivative, is currently in late-stage clinical development for the radical cure of P. vivax. Here drug interactions between TFQ and chloroquine and six artemisinin-combination therapy (ACT) partner drugs in P. falciparum asexual stages and gametocytes were investigated. TFQ was mostly synergistic with the ACT-partner drugs in asexual parasites regardless of genetic backgrounds. However, at fixed ratios of 1:3, 1:1 and 3:1, TFQ only interacted synergistically with naphthoquine, pyronaridine and piperaquine in gametocytes. This study indicated that TFQ and ACT-partner drugs will likely have increased potency against asexual stages of the malaria parasites, whereas some drugs may interfere with each other against the P. falciparum gametocytes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358947 | PMC |
| http://dx.doi.org/10.1016/j.ijpddr.2017.03.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Haplotypes of Chloroquine Resistance Marker Genes Among Uncomplicated Malaria Cases in Lagos, Nigeria.
Biochem Genet
January 2025
Key Laboratory of Parasite and Vector Biology of the Chinese Ministry of Health, Chinese Center for Disease Control and Prevention, WHO Collaborating Centre for Tropical Diseases, National Institute of Parasitic Diseases, Shanghai, 200025, People's Republic of China.
Drug resistance resulting from mutations in Plasmodium falciparum, that caused the failure of previously effective malaria drugs, has continued to threaten the global malaria elimination goal. This study describes the profiles of P. falciparum chloroquine resistance transporter (Pfcrt) and P.
View Article and Find Full Text PDFThe spread of molecular markers of artemisinin partial resistance and diagnostic evasion in Eritrea: a retrospective molecular epidemiology study.
Lancet Microbe
December 2024
Drug Resistance and Diagnostics, Australian Defence Force Malaria and Infectious Disease Institute, Gallipolli Barracks, Enoggera, QLD, Australia; Australian Defence Force Malaria and Infectious Disease Institute Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia. Electronic address:
Background: Eritrea was the first African country to discontinue the use of histidine rich protein 2 (HRP2)-detecting rapid diagnostic tests (RDTs) for malaria diagnosis following reports of a high prevalence of pfhrp2/3-deleted Plasmodium falciparum parasites causing false-negative results in the country. Eritrea was also the first African country to report partial artemisinin resistance due to the P falciparum kelch13 (pfk13) Arg622Ile mutation. We aimed to characterise the spatial distribution of pfk13 mutants and their interactions with pfhrp2/3 deletions in Eritrea and to assess the role of the use of HRP2-detecting RDTs and antimalarial (artesunate-amodiaquine) therapy in the spread of the two variants.
View Article and Find Full Text PDFPopulation genomics and transcriptomics of Plasmodium falciparum in Cambodia and Vietnam uncover key components of the artemisinin resistance genetic background.
Nat Commun
December 2024
School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
The emergence of Plasmodium falciparum parasites resistant to artemisinins compromises the efficacy of Artemisinin Combination Therapies (ACTs), the global first-line malaria treatment. Artemisinin resistance is a complex genetic trait in which nonsynonymous SNPs in PfK13 cooperate with other genetic variations. Here, we present population genomic/transcriptomic analyses of P.
View Article and Find Full Text PDFRecent Advances in the Treatment of Malaria.
Pharmaceutics
November 2024
Department of Infection and Immunity, King Faisal Specialist Hospital & Research Center, Riyadh 11211, Saudi Arabia.
Article Synopsis
- * The primary current treatment is artemisinin-based combination therapies (ACTs), but rising resistance to these drugs, particularly in Southeast Asia, threatens advancements made in battling the disease.
- * The review explores various antimalarial drugs, challenges of drug resistance, and the importance of new therapies and vaccines in the ongoing fight against malaria and aims for its eventual eradication.
Temporal genomics in Southern Zambia shows rising prevalence of Plasmodium falciparum mutations linked to delayed clearance after artemisinin-lumefantrine treatment.
Sci Rep
November 2024
Department of Pathology and Laboratory Medicine, Brown University, Providence, RI, 02906, USA.
Article Synopsis
- * In a study in southern Zambia from 2013 to 2018, researchers genotyped 85.5% of Plasmodium falciparum samples, finding only one sample with a known resistance mutation and identifying five new mutations with low prevalence.
- * A significant 13% of isolates showed a mutation linked to delayed treatment clearance, which increased in prevalence over the study period, indicating that while common resistance mutations are rare, others may be evolving in response to selection pressures.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!